A novel dosimetric metrics-based risk model to predict local recurrence in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy

Table 1 Clinical characteristics of patients with and without recurrence

Variable	Entire cohort		P value	PSM cohort		P value
Variable	Recurrent (n = 44)	Non-recurrent (n = 449)	P value	Recurrent (n = 44)	Non-recurrent (n = 88)	P value
Age			0.068			0.705
≤ 46	16 (36.4)	228 (50.8)		16 (36.4)	35 (39.8)
> 46	28 (63.6)	221 (49.2)		28 (63.6)	53 (60.2)
Gender			0.382			0.432
Male	34 (77.3)	319 (71.0)		34 (77.3)	73 (82.9)
Female	10 (22.7)	130 (29.0)		10 (22.7)	15 (17.1)
T classification			0.593			0.255
T1-2	14 (31.8)	161 (35.9)		14 (31.8)	37 (42.0)
T3-4	30 (68.2)	288 (64.1)		30 (68.2)	51 (58.0)
N classification			0.822			0.803
N0-1	19 (43.2)	186 (40.5)		19 (43.2)	36 (40.9)
N2-3	25 (56.8)	263 (58.5)		25 (56.8)	52 (59.1)
IC			0.272^*			0.550^*
Yes	38 (86.4)	410 (91.3)		38 (86.4)	80 (90.9)
No	6 (13.6)	39 (8.7)		6 (13.6)	8 (9.1)
CC			0.042			0.170
Yes	32 (72.7)	380 (84.6)		32 (72.7)	73 (82.9)
No	12 (27.3)	69 (15.4)		12 (27.3)	15 (17.1)
AC			0.246			0.368
Yes	18 (40.9)	145 (32.3)		18 (40.9)	29 (33.0)
No	26 (59.1)	304 (67.7)		26 (59.1)	59 (67.0)
Prescription						0.119
70 Gy	25 (56.8)	312 (69.5)	0.085	25 (56.8)	62 (70.5)
74 Gy	19 (43.2)	137 (30.5)		19 (43.2)	26 (29.5)
RT technique			0.485			0.318
IMRT	21 (47.7)	239 (53.2)		21 (47.7)	34 (38.6)
VMAT	23 (52.3)	210 (46.8)		23 (52.3)	54 (61.4)

IC, induction chemotherapy; CC, concurrent chemotherapy; AC, adjuvant chemotherapy; RT, radiotherapy; IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy
P values were calculated by χ² test or Fisher’ exact test (^*)

ISSN: 1748-717X